MU

Marianne Uteng

Managing Director at Novartis Venture Fund

Basel Metropolitan Area

VC

Invests in

Stages:

Series A
Seed

  • Min Investment:

    $5,000,000.00

  • Max Investment:

    $10,000,000.00

  • Target Investment:

    $7,500,000.00

Skills

Venture Capital
Biomarkers
Biotechnology
Biomarker Discovery
Clinical Development
Clinical Trials
Drug Development
Drug Discovery
In Vitro
Biochemistry
Lifesciences
Molecular Biology
NMR
Oncology
Peptides
Pharmaceutical Industry
Structure Elucidation
Toxicology
Cell
Life Sciences

Education

  • PhD

    European Molecular Biology Laboratory (EMBL)

    (2003 - 2008)

  • Master's degree

    University of Oslo

    (1997 - 2003)

Investments

CatalYm

Series C

Total Funding: $200M

AstronauTx

Series A

Total Funding: $60M

Tagworks Pharmaceuticals

Series A

Total Funding: $65M

Epsilogen

Series B

Total Funding: $47M

Work Experience

Novartis

2023

  • Managing Director at Novartis Venture Fund

    2023

AstronauTx

2023

  • Member Board of Directors

    2023

Tagworks Pharmaceuticals

2023

  • Member Board of Directors

    2023

Epsilogen Ltd

2022

  • Board Director

    2022

CatalYm GmbH

2021

  • Board Observer

    2022

  • Board Director

    2021 - 2022

Amphista Therapeutics Limited

2021

  • Board Observer

    2021

Rappta Therapeutics

2020

  • Board Observer

    2020